This transcript provides a focused pathological discussion of Dermatofibrosarcoma Protuberans (DFSP), emphasizing its distinct histological pattern of fat entrapment in the subcutaneous tissue, often creating a "honeycomb" appearance. The speaker highlights the crucial diagnostic challenge of differentiating DFSP from diffuse neurofibroma, which shares features like bland, spindle-cell morphology and fat entrapment. Immunohistochemistry protocols are reviewed, stressing the need for the combination of CD34 (diffuse in DFSP) and S100 (negative in DFSP, positive in neurofibroma) to avoid misdiagnosis, as CD34 alone is unreliable. The video concludes by detailing the definitive genetic marker—the COL1A1-PDGFB translocation (17;22)—and its therapeutic implication: using tyrosine kinase inhibitors (like Imatinib) for advanced disease. Although metastasis is rare, DFSP is associated with high recurrence rates and significant patient morbidity due to necessary extensive surgical resections.
0:07 Histological Hallmark: DFSP is characterized by its infiltration and entrapment of fat in the subcutaneous tissue, creating a distinct "honeycomb pattern."
0:21 Differential Diagnosis (DDx): The most challenging DDx is diffuse neurofibroma, as both tumors feature bland, thin, spindle-shaped cells, a myxoid/collagenous background, and fat entrapment.
0:49 IHC Limitations: Factor 13a is generally not helpful. While DFSP is typically strong/diffuse for CD34, approximately 70% of neurofibromas can also be CD34 positive, making CD34 unreliable as a standalone diagnostic tool.
1:19 Critical IHC Panel: To distinguish DFSP from neurofibroma, the combined use of CD34 (positive in DFSP) and S100 (negative in DFSP, positive in neurofibroma) is necessary.
1:51 Defining Translocation: DFSP is defined by the characteristic 17;22 translocation, which fuses the Collagen 1 (COL1A1) gene with the Platelet-Derived Growth Factor Beta (PDGFB) gene.
2:01 Targeted Therapy: Because the PDGF-beta fusion protein acts as a tyrosine kinase, inhibitors (TKIs) can be used to treat large or metastasizing DFSPs, such as Imatinib, though they typically manage rather than cure the disease.
2:15 Storiform Pattern: The classic "storiform" (swirled) pattern is often described but is frequently subtle and less diagnostically helpful than the fat entrapment or cellular blandness, as it can occur in other tumors like dermatofibroma.
2:38 Prognosis and Morbidity: While DFSP rarely metastasizes, recurrence is a major clinical problem, necessitating large, extensive surgeries and resulting in significant patient morbidity.